Study of ibuzatrelvir for immunocompromised adults with COVID-19
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests an investigational medicine called ibuzatrelvir for adults with COVID-19 who have a weakened immune system. The study aims to see if it helps them recover and avoid severe illness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have tested positive for COVID-19 and have symptoms that started within the last 5 days.
- Your COVID-19 symptoms are mild or moderate (not severe), and you do not need extra oxygen.
- You have a severely weakened immune system due to certain conditions or treatments, such as an organ transplant or recent cancer treatment.
- You are not currently on dialysis for kidney failure.
- You are not pregnant or breastfeeding.
- You have not taken other antiviral medications for this COVID-19 infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new HIV medications, islatravir and ulonivirine, in people who have never taken HIV treatment before. It aims to see if this combination can safely control the virus.
This trial tests if a new medicine called ibuzatrelvir can help people with COVID-19 who have certain health risks avoid severe illness. It is for patients who cannot or choose not to take another COVID-19 pill called Paxlovid.
This study looks at how well antiviral treatments work in people with weakened immune systems who get COVID-19. It focuses on patients treated with two specific antivirals and aims to understand their outcomes.
This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.
This trial tests a longer course of remdesivir plus Paxlovid (nirmatrelvir/ritonavir) for immunocompromised people with persistent COVID-19. It aims to see if combining these two antiviral medicines can help clear the virus more effectively.
This trial tests a new drug, ratutrelvir, for people with mild to moderate COVID-19. It aims to find a safe and effective dose to help you feel better faster.
Hear when a new COVID-19 Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.